Two surgical procedures have been described for ICRS implantation: the mechanical method and the femtolaser method. The use of femtolaser for ICRS tunnel creation was widely accepted after FDA ...

Please provide your email address to receive an email when new articles are posted on . Classic textbooks teach that the incidence of keratoconus is one per 2,000. That would equate to about 170,000 ...

Please provide your email address to receive an email when new articles are posted on . Patients who underwent cross-linking were younger and white and had commercial insurance. Patients treated with ...

Carolina Cataract & Laser Center (CCLC) announced on April 29 that David Vroman, M.D., is the first physician in South ...

On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...

Glaukos GKOS announced that its innovative keratoconus treatment, Epioxa (Epioxa HD / Epioxa), was assigned a permanent HCPCS J-code — J2789 — by the U.S. Centers for Medicare and Medicaid Services ...

Glaukos (GKOS) announced the submission of its New Drug Application NDA to the U.S. Food and Drug Administration FDA or Epioxa or Epi-on, its next-generation corneal cross-linking iLink therapy for ...

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a ...

Keratoconus is a progressive eye condition that affects the shape and clarity of the cornea, often beginning in the teenage years or early adulthood. As the cornea thins and bulges into a cone-like ...

Keratoconus is a progressive eye disease that weakens and thins the cornea, the clear front surface of the eye. In its early, ...